Cellares Automates Gene-Corrected HSPC Manufacturing

Company Cellares / Papillon Therapeutics Event Type Manufacturing Collaboration Modality Autologous Gene-Corrected HSPC Cell Therapy Asset PPL-001 Target FXN (GAA Repeat Expansion Correction) Disease Area Friedreich’s Ataxia Summary Cellares and Papillon will automate manufacturing and release testing for PPL-001, an autologous gene-corrected hematopoietic stem and…